Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from managed care entities. These insurers are https://adrianakozt068486.jts-blog.com/40588192/the-medication-faces-is-encountering-managed-care-organization-hurdles-a-look-at-reimbursement-disputes